Filing Details

Accession Number:
0001968202-24-000090
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-03 16:06:02
Reporting Period:
2024-04-01
Accepted Time:
2024-04-03 16:06:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc. REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1187443 F Arthur Ryan 777 Old Saw Mill River Road
Tarrytown NY 10591
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-04-01 2 $957.78 18,280 No 4 S Direct
Common Stock Disposition 2024-04-01 2 $958.86 18,278 No 4 S Direct
Common Stock Disposition 2024-04-01 9 $959.47 18,269 No 4 S Direct
Common Stock Disposition 2024-04-01 15 $960.53 18,254 No 4 S Direct
Common Stock Disposition 2024-04-01 14 $961.59 18,240 No 4 S Direct
Common Stock Disposition 2024-04-01 9 $962.42 18,231 No 4 S Direct
Common Stock Disposition 2024-04-01 20 $963.60 18,211 No 4 S Direct
Common Stock Disposition 2024-04-01 16 $964.45 18,195 No 4 S Direct
Common Stock Disposition 2024-04-01 13 $965.35 18,182 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023.
  2. Represents volume-weighted average price of sales of 9 shares of Company stock on April 1, 2024 at prices ranging from $959.13 to $959.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.
  3. Represents volume-weighted average price of sales of 15 shares of Company stock on April 1, 2024 at prices ranging from $960.06 to $960.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.
  4. Represents volume-weighted average price of sales of 14 shares of Company stock on April 1, 2024 at prices ranging from $961.10 to $961.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.
  5. Represents volume-weighted average price of sales of 9 shares of Company stock on April 1, 2024 at prices ranging from $962.06 to $962.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.
  6. Represents volume-weighted average price of sales of 20 shares of Company stock on April 1, 2024 at prices ranging from $963.02 to $963.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.
  7. Represents volume-weighted average price of sales of 16 shares of Company stock on April 1, 2024 at prices ranging from $964.02 to $964.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.
  8. Represents volume-weighted average price of sales of 13 shares of Company stock on April 1, 2024 at prices ranging from $965.00 to $965.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.